225. 先天性腎性尿崩症 Congenital nephrogenic diabetes insipidus Clinical trials / Disease details

臨床試験数 : 15 / 薬物数 : 48 - (DrugBank : 18) / 標的遺伝子数 : 31 - 標的パスウェイ数 : 65

3 trials found

diseases per page:

Showing 1 to 3 of 3 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05190744 (ClinicalTrials.gov)	March 1, 2022	29/12/2021	PB to Treat Hereditary Nephrogenic Diabetes Insipidus, ADPKD Treated With Tolvaptan, and Severely Po ...	A Multi-center, Open-Label, Exploratory Study to Assess the Efficacy of PB in Decreasing the Urine O ...	Autosomal Dominant Polycystic Kidney Disease;Nephrogenic Diabetes Insipidus;Acquired Nephrogenic Dia ...	Drug: PB	Mayo Clinic	Hopital du Sacre-Coeur de Montreal	Recruiting	18 Years	N/A	All	20	Phase 2	United States
2	JPRN-jRCTs031180369	12/04/2018	18/03/2019	Tolvaptan for nephrogenic diabetes insipidus	Exploratory study of tolvaptanuse for nephrogenic diabetes insipidus caused by mutation in vasopress ...	Nephrogenic diabetes insipidus Nephrogenic diabetes insipidus, polyuria;D018500	Starting tolvaptan from 60 mg and dose up to 90mg and 120mg in every 1 or 2 days.	Makita Noriko	NULL	Recruiting	>= 20age old	Not applicable	Both	3	Phase 1-2	Japan
3	JPRN-UMIN000021708	2016/04/18	18/04/2016	A study to evaluate effect and safety of Tolvaptanin Nephrogenic Diabetes Insipidus caused by mutati ...	A study to evaluate effect and safety of Tolvaptanin Nephrogenic Diabetes Insipidus caused by mutati ...	Nephrogenic Diabetes Insipidus caused by mutations in the vasopressin type 2 receptor gene	Administration of Tolvaptan once per day (60mg/day, 90mg/day, 120mg/day), each dose for two days.	Department of Nephrology and Endocrinology, The University of Tokyo Hospital	NULL	Recruiting	20years-old	Not applicable	Male and Female	3	Not selected	Japan

First Previous1Next Last